Weekly chemo could be easier on elderly sarcoma patients
NCT ID NCT07125183
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether giving the chemotherapy drug doxorubicin weekly at a lower dose is effective and easier to tolerate for people aged 65 to 100 with advanced leiomyosarcoma, a type of soft tissue cancer. The standard dose often causes harsh side effects, especially in older or frailer patients. Researchers will track how long the cancer stays under control and how patients feel during treatment.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
doxorubicin (a chemotherapy drug)
What this could lead to
If successful, this could offer a better-tolerated chemotherapy option for elderly patients with advanced leiomyosarcoma, potentially improving quality of life while controlling tumor growth.
What could go wrong
This is a small early-phase trial with only 20 participants, so results may not apply broadly. The lower dose may also be less effective at stopping cancer progression.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SARCOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
University Of Colorado Hospital
RECRUITINGAurora, Colorado, 80045, United States
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••